Does TRICARE Cover Saxenda?

TRICARE Formulary Status for Saxenda

Saxenda (liraglutide 3 mg) is listed on the TRICARE formulary as a non-preferred brand medication for chronic weight management. This means it is available but sits behind preferred alternatives that TRICARE's pharmacy benefit managers favor first. Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) both hold preferred status with prior authorization on the TRICARE formulary [1].

The distinction between preferred and non-preferred matters for two reasons. First, your copay is higher for non-preferred drugs. Active-duty family members and retirees using TRICARE retail pharmacy pay $34 for a preferred brand versus $68 for a non-preferred brand for a 30-day supply at retail, according to 2025 TRICARE pharmacy copay schedules. Second, non-preferred status triggers mandatory step therapy, meaning you must try and fail a preferred agent before TRICARE will authorize Saxenda.

TRICARE's Pharmacy Operations Directorate manages the Uniform Formulary through the Department of Defense (DoD) Pharmacoeconomic Center. The Basic Core Formulary is reviewed quarterly, and drug tier placements can shift based on clinical evidence, pricing negotiations, and therapeutic class reviews [2]. Beneficiaries should verify current status through the TRICARE formulary search tool or by calling Express Scripts, TRICARE's pharmacy contractor, at the number on the back of their military ID.

Prior Authorization Requirements

TRICARE requires prior authorization (PA) for Saxenda. The process is rated as moderate difficulty, meaning approvals are possible but not automatic. Your prescribing provider must submit clinical documentation that meets specific criteria before TRICARE will approve the claim.

The standard PA criteria for GLP-1 receptor agonists used in weight management on TRICARE include: a confirmed BMI of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia. The prescriber must also document that the patient has attempted lifestyle modifications (diet and exercise) for a minimum period, typically 3 to 6 months, before pharmacotherapy [3].

For Saxenda specifically, because it sits in non-preferred status, TRICARE also requires documentation that a preferred GLP-1 agent was tried and either failed or caused intolerable side effects. This is the step therapy requirement. A letter from the prescribing physician explaining clinical rationale for Saxenda over preferred alternatives strengthens the application.

PA requests go through Express Scripts. Turnaround time is typically 48 to 72 hours for standard requests, though urgent requests can be processed within 24 hours. If the PA is approved, it is generally valid for 12 months, after which renewal documentation must be submitted.

Step Therapy: What TRICARE Expects You to Try First

Step therapy is a cost-control mechanism that requires patients to try lower-cost or preferred medications before a plan will cover a more expensive option. TRICARE applies step therapy to Saxenda within the GLP-1 weight management class.

In practice, this means your provider must prescribe Wegovy or Zepbound first. You need to use the preferred agent for a minimum period (often 90 days) and demonstrate that it was either clinically ineffective (defined as less than 5% total body weight loss) or caused adverse effects that warranted discontinuation [4]. If you lost adequate weight on a preferred agent, TRICARE has little reason to authorize Saxenda, since liraglutide 3 mg produced 8.0% mean body weight loss in the SCALE Obesity and Prediabetes trial (N=3,731) at 56 weeks versus 2.6% with placebo [5], while semaglutide 2.4 mg (Wegovy) produced 14.9% mean weight loss at 68 weeks in the STEP 1 trial (N=1,961) [6].

There are exceptions. If you have a documented allergy or contraindication to semaglutide or tirzepatide, your provider can request a step therapy override. A prior adverse drug reaction report filed in your military medical record strengthens this request.

One practical consideration: some military treatment facilities (MTFs) may stock liraglutide 3 mg in their on-site pharmacies for specific patient populations. Medications dispensed at MTF pharmacies have no copay for any TRICARE beneficiary, which can bypass the formulary tier cost differential entirely. Ask your PCM whether the MTF pharmacy carries Saxenda before routing through retail or mail-order channels.

How to Appeal a TRICARE Denial of Saxenda

If TRICARE denies your Saxenda PA request, you have structured appeal rights. The process involves multiple levels, and persistence matters. According to TRICARE's published appeals data, a meaningful percentage of initial pharmacy denials are overturned on first appeal when supported by adequate clinical documentation.

First-level appeal. Submit a written appeal to the TRICARE ECHO contractor (currently Express Scripts for pharmacy benefits). Include a letter of medical necessity from your prescribing provider, relevant clinical records, documentation of step therapy failure, and any supporting literature. The contractor must respond within 30 calendar days for standard appeals or 72 hours for expedited appeals involving urgent clinical need.

Second-level appeal. If the first appeal is denied, you can escalate to the TRICARE Regional Office. This review is conducted by an independent medical reviewer who was not involved in the original decision. Additional documentation or specialist consultation notes can be submitted at this stage.

Third-level appeal. Further denial can be appealed to the Defense Health Agency (DHA). This is the final administrative level within the TRICARE system.

Dr. Craig Primack, MD, FACP, past president of the Obesity Medicine Association, has noted: "Military beneficiaries often have strong appeal cases when they can show documented failure of formulary-preferred agents combined with a clinical rationale for why a specific GLP-1 receptor agonist is medically appropriate for their situation." Providing a clear clinical narrative rather than simply checking boxes on a form increases the likelihood of reversal.

Key tips for a successful appeal: include specific dates and durations of prior medication trials, quantify weight change (or lack thereof) on preferred agents, list side effects with severity grades, and reference the FDA-approved indication for Saxenda in your BMI category [7].

Cost Breakdown: What You Will Pay Out of Pocket

The financial picture for Saxenda on TRICARE varies significantly based on your beneficiary category and where you fill the prescription. Saxenda's manufacturer list price is $1,349 per month [8]. Without any insurance coverage, that is the cash-pay cost at most retail pharmacies.

With TRICARE coverage and an approved PA, costs break down as follows:

Active-duty service members (ADSMs). Prescriptions filled at MTF pharmacies or through the TRICARE mail-order pharmacy (Express Scripts) carry zero copay. Retail pharmacy copay for non-preferred brands is $34 per 30-day supply.

TRICARE Prime (non-ADSM). MTF pharmacy: $0. Mail-order: $20 for non-preferred brand (90-day supply). Retail: $34 for non-preferred brand (30-day supply).

TRICARE Select. Retail: $68 for non-preferred brand (30-day supply) after deductible is met. Mail-order: $68 for a 90-day supply of non-preferred brands.

TRICARE For Life (age 65+). Copays align with Medicare Part D cost-sharing, and Saxenda is not covered under standard Medicare Part D, creating a potential gap. TFL beneficiaries should consult with their benefits advisor about coverage specifics for anti-obesity medications [9].

These copay amounts assume Saxenda is on the covered non-preferred tier with an active PA. Without PA approval, the entire $1,349 monthly cost falls to the patient.

Can You Use the Novo Nordisk Savings Card with TRICARE?

No. Manufacturer savings cards and copay assistance programs from Novo Nordisk (Saxenda's manufacturer) cannot be used with TRICARE or any federal insurance program. This restriction applies to all government-sponsored insurance including TRICARE, Medicare, Medicaid, and VA benefits [10].

The legal basis is the federal Anti-Kickback Statute, which prohibits pharmaceutical manufacturers from offering financial incentives that could influence prescribing decisions for patients covered by federal healthcare programs. Novo Nordisk's Saxenda savings card explicitly states in its terms and conditions that it is not valid for patients whose prescriptions are reimbursed, in whole or in part, by any federal or state government program.

For TRICARE beneficiaries seeking to reduce costs, the most effective strategy is to fill prescriptions through MTF pharmacies (zero copay) or TRICARE mail-order (reduced copay). If Saxenda is denied and you choose to pay cash, GoodRx and similar discount platforms may reduce the retail price to approximately $1,100 to $1,250 per month at certain pharmacies, though this varies by location.

Saxenda vs. Covered Alternatives on TRICARE

Given that Wegovy and Zepbound carry preferred status on the TRICARE formulary, many beneficiaries will find that trying a preferred agent first is both a formulary requirement and a clinically reasonable starting point.

In the SCALE Obesity and Prediabetes trial, liraglutide 3 mg (Saxenda) produced a mean weight loss of 8.0% of body weight over 56 weeks, with 63.2% of participants achieving at least 5% weight loss versus 27.1% on placebo [5]. The STEP 1 trial showed semaglutide 2.4 mg (Wegovy) produced 14.9% mean weight loss over 68 weeks, with 86.4% achieving at least 5% loss [6]. The SURMOUNT-1 trial demonstrated tirzepatide 15 mg (Zepbound) produced 22.5% mean weight loss over 72 weeks (N=2,539) [11].

Dr. Beverly Tchang, MD, an endocrinologist at Weill Cornell Medicine, has stated: "Liraglutide remains a reasonable option for patients who cannot tolerate semaglutide or tirzepatide, or for those who prefer a daily injection over a weekly one. The GLP-1 class has a spectrum of efficacy and tolerability, and the right medication is the one the patient will consistently use."

The daily dosing schedule of Saxenda (versus weekly for Wegovy and Zepbound) can be either an advantage or a disadvantage depending on patient preference. Some patients prefer the ability to skip a dose on days with expected nausea triggers, while others prefer the convenience of once-weekly administration. The titration schedule for Saxenda takes 4 weeks to reach the therapeutic dose of 3 mg, while Wegovy takes approximately 16 to 20 weeks of dose escalation [7][12].

TRICARE Coverage by Plan Type

Not all TRICARE plans handle Saxenda identically. Coverage policies for anti-obesity medications have expanded across DoD health plans in recent years, but differences remain.

TRICARE Prime and TRICARE Select both include pharmacy benefits that cover FDA-approved anti-obesity medications with prior authorization. The formulary is identical across these plans. The difference is in cost-sharing structure, not drug availability.

TRICARE Reserve Select (TRS) and TRICARE Retired Reserve (TRR) follow the same Uniform Formulary but may have different copay tiers. Beneficiaries in these plans should verify specific cost-sharing amounts through their plan documents.

TRICARE Overseas. Beneficiaries stationed outside the United States access medications through the TRICARE Overseas Program (TOP). Saxenda availability may be limited by local pharmacy stock. The International SOS contractor manages overseas pharmacy benefits, and PA requirements still apply [13].

TRICARE Young Adult (TYA). Dependents aged 21 to 26 on TYA plans have pharmacy benefits that mirror TRICARE Select. Saxenda coverage requires the same PA and step therapy documentation.

One consistent rule applies across all plan types: anti-obesity medications are covered only for the FDA-approved indication (chronic weight management in adults meeting BMI criteria). Off-label use for other purposes will not receive PA approval through TRICARE pharmacy channels.

Timeline: From Prescription to First Injection

Understanding the typical timeline helps set expectations. Here is a realistic sequence for a TRICARE beneficiary pursuing Saxenda coverage:

Week 1. Schedule an appointment with your PCM or an obesity medicine specialist at your MTF or network provider. Discuss weight management history, prior medication trials, and clinical need for pharmacotherapy.

Weeks 1 to 2. Provider submits PA request to Express Scripts with supporting documentation. If step therapy applies, documentation of prior preferred-agent trial is included.

Weeks 2 to 3. PA decision returned (48 to 72 hours standard, but allow for delays). If approved, prescription can be filled. If denied, provider receives denial rationale.

Weeks 3 to 5 (if denied). First-level appeal submitted with additional documentation. Response within 30 days for standard appeal. Expedited review available if clinically indicated.

Weeks 5 to 9 (if first appeal denied). Second-level appeal to TRICARE Regional Office. Allow 30 to 60 days for independent review.

For beneficiaries who qualify without step therapy complications (for example, those with documented semaglutide allergy), the prescription-to-injection timeline can be as short as 5 to 7 days from the initial provider visit.